Date: 18 November 2020
Author(s): Hudson Lockett in Hong Kong and Christian Shepherd in Beijing
Source: Financial Times
Earlier this week, news of Pfizer and Moderna’s coronavirus vaccines successful results positively impacted the market. However, these successful trials have also heavily impacted the Chinese pharmaceuticals industry, slicing more than $13bn off the market capitalisation and cutting off Beijing’s ambition to be the market leader in the fight against the virus.
Since the first news of the Pfizer’s effective phase-three trial results was announced earlier this month, 14 vaccine producers listed in Shanghai and Shenzhen have dropped 11 per cent, down by a third from its peak in August.
But analysts said support from Beijing and confidence that Chinese producers would be the first to tap demand in developing markets have helped stabilise the companies’ share prices. Their total market value was up almost 125 per cent this year at more than Rmb1tn ($159.7bn), according to data provider Wind.
However, these companies share prices have stabilised and analysts shares that contributing factors such as support from Beijing and confidence that Chinese producers would be the first to quench demand in developing markets were critical.
With the country’s swift success in containing the virus, this complicated the Chinese developers progress in their vaccine development, forcing them to perform final-stage clinical trials in other countries.
Sensitivities in reaching pricing and distribution deals with host countries have led to delays in phase-three trials, which test the effectiveness of a vaccine in the general population and are necessary for regulators to approve commercial sales.
Chinese officials however, are sticking to the ambitious timeline for manufacturing and distribution in attempts to ensure their position as market leader suppliers for their vaccine developers, and to bolster diplomatic ties.
A day after the Pfizer announcement, top officials in Beijing said China had “provided a great number of anti-epidemic resources to countries the world over through commercial channels”.
Brock Silvers, chief investment officer at Kaiyuan Capital, said state support for pharmaceutical and biotech listings had helped drive a number of initial public offerings in China that “mostly did well, and the ensuing gold rush attracted strong retail [investor] support”.
But while the sell-off of vaccine producer shares had slowed, Mr Silvers said the market remained unsettled. “Reduced support is likely to be highly correlated to continued positive announcements from foreign vaccine developers,” he said.
Bruce Pang, head of macro and strategy research at China Renaissance, said Beijing’s support had helped bolster investor confidence in domestic producers. He said vaccines from Pfizer and Moderna required refrigeration to remain viable, which could leave them at a disadvantage in developing markets.
“Those limitations are bad for use in developing countries but that’s not the case with Chinese vaccines [most of which are] relatively easier to produce, store and distribute,” Mr Pang said.
Zhang Tong, a pharmaceutical equities analyst at Kaifeng Investment, said there “definitely was a bubble in the vaccine sector before”. But he said there was room for growth once the market correction ended.
Sterling House Trust is a private trust with a difference. It offers its members an exclusive and reliable platform to access unique opportunities and lifestyle services reserved for the select few. With its team of professional managers Sterling House Trust constantly scans the markets and collaborate with reliable global partners to create a portfolio of carefully curated programmes for its members. Members can access these programmes according to their individual needs, interest and financial capacity. Sterling House Trust is headquartered in Auckland, New Zealand, and has operations based in London, UK.
The Sterling House Trust platform was established with the objective of providing its members, secure access to opportunities across a range of global locations, sectors and services.
Our unique Platform was established within the framework of a trust so that the trust would have oversight and governance over the range of services and its quality. Member protection is a core principle and drive in all that we do. Our trustees ensures that the interests and quality of service provided by the Platform are always maintained at the highest standards.
The trust and its trustees provide robust oversight and is constantly on the move to identify and shortlist select opportunities in the international markets. Likewise, we apply the same stringent standards in identifying and selecting providers and professional partners to join our Platform.
The Sterling House Trust Platform utilises our international footfall and relationships to provide our members with access to a range of international opportunities via our global network which covers a broad range of sectors including:
Asset protection, international property ownership and management, alternative and direct ownership, estate planning, banking services, foreign exchange, card services, alternative investment and lifestyle services.
New Zealand Head Office
31/335 Lincoln Road,
14-16 Dowgate Hill,
England EC4R 2SU